Macrogenics (MGNX) Other financing activities (2013 - 2025)

Macrogenics' (MGNX) quarterly Other financing activities came in at $70.0 million in Q2 2025, up 40.0% on a QoQ basis from $50.0 million in Q3 2023.

Macrogenics (MGNX) Other financing activities (2013 - 2025) Analysis & Trends

Macrogenics (MGNX) has 7 years of Other financing activities data on file, last reported at $70.0 million in Q2 2025.

On a quarterly basis, Other financing activities changed N/A year-over-year to $70.0 million in Q2 2025; TTM through Dec 2025 was $120.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $70.0 million, changed N/A from the prior year.
Other financing activities for Q2 2025 stood at $70.0 million, up from $50.0 million in the prior quarter.
Over the last five years, Other financing activities for MGNX reached as high as $100.0 million in Q1 2023 and fell as low as $50.0 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Macrogenics	254.43 Mn	187.92 Mn	-

Download Data